First Patient Receives Dose of LJPC-401

Home  /  News & Information  /  Current Page



SAN DIEGO, Oct 19, 2015 (BUSINESS WIRE) — La Jolla Pharmaceutical Company LJPC, +7.39% (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that the first patient has been dosed in a Phase 1 clinical trial of LJPC-401, La Jolla’s novel formulation of hepcidin.

More information:

%d bloggers like this: